Tirzepatide for Weight Loss Cost (2026)

Brand-name Zepbound retails at approximately $1,000 to $1,300 per month without insurance in 2026. Compounded tirzepatide from licensed 503A pharmacies through telehealth weight-loss clinics typically runs $250 to $600 per month. With insurance coverage for Zepbound, out-of-pocket can be $25 to $100 monthly with prior authorization. Medicare does not cover for obesity but does cover Mounjaro for type 2 diabetes.

Yes, in head-to-head and indirect trial comparisons, tirzepatide delivers slightly greater average weight loss: 18-22 percent at 72 weeks (SURMOUNT-1) versus 12-17 percent at 68 weeks for semaglutide (STEP 1). The difference is roughly 4-6 percentage points of body weight. The SURPASS-2 trial directly compared the two in type 2 diabetes and found tirzepatide superior on weight loss and A1c reduction.

Both contain the same active molecule (tirzepatide). Zepbound is FDA-approved for chronic weight management at doses up to 15 mg/week. Mounjaro is FDA-approved for type 2 diabetes at doses up to 15 mg/week. The medications are functionally identical; the brand split is for indication-specific marketing and insurance formulary purposes.

Published clinical trials show average weight loss of 18-22 percent of starting body weight at 72 weeks on the maximum dose (15 mg/week). For a 220-pound starting weight, that is approximately 40-48 pounds. About 90 percent of patients achieve at least 5 percent weight loss; about 50 percent achieve at least 20 percent.

Compounded tirzepatide from licensed 503A pharmacies using FDA-approved API is widely considered safe by clinicians, though it carries less manufacturing oversight than brand-name Zepbound. Risks include variable potency, contamination, and use of unapproved salt forms by lower-quality compounders. Following the FDA resolution of the tirzepatide shortage in October 2024, compounding pathways have tightened. Verify your clinic uses an FDA-registered 503A pharmacy with FDA-approved API.

Studies show approximately 60-70 percent of weight lost on tirzepatide is regained within 12-24 months of stopping. Most patients require ongoing maintenance dosing (often at reduced dose) or substantial lifestyle restructuring to maintain weight loss long-term. Tirzepatide is generally considered a long-term or indefinite medication for chronic weight management.

The most common side effects are gastrointestinal: nausea (25-40 percent), constipation (15-25 percent), diarrhea (15-25 percent), and vomiting (10-15 percent). Side effects are most pronounced during dose increases. Rare but serious side effects include gallbladder disease (1-2 percent), pancreatitis (less than 0.5 percent), and theoretical risk of thyroid C-cell tumors (not confirmed in humans).

Approximately 25 to 40 percent of weight lost on tirzepatide is lean mass, similar to semaglutide. Resistance training 2-3 times per week and adequate protein intake (1.0-1.2 grams per kg body weight) during use substantially mitigate muscle loss.

Coverage varies widely. Many commercial insurance plans cover Zepbound for obesity (BMI 30+) with prior authorization, though coverage is less broad than for semaglutide due to newer launch. Medicare does not cover Zepbound for obesity. Mounjaro for type 2 diabetes is more frequently covered. Compounded versions are generally not covered.

Tirzepatide is injected subcutaneously once weekly. Common injection sites are the abdomen, the front of the thigh, or the back of the upper arm. Brand-name Zepbound comes in pre-filled pens with a fixed dose; compounded tirzepatide is typically drawn from a multi-dose vial into a syringe.

No. Both medications act on overlapping receptor pathways. Combining them substantially increases side effect risk without proportional benefit and is not supported by evidence. Standard practice is one or the other.

No. Tirzepatide is a weight-loss medication. Significant lean mass is often lost during weight loss on tirzepatide unless resistance training and adequate protein intake are maintained. Tirzepatide does not have anabolic effects on muscle.

Alcohol is not contraindicated but is often poorly tolerated. Many patients report reduced alcohol cravings on tirzepatide. Some report intensified hangovers or stomach upset from drinking.